Goroh Okazaki, MD
Family Medicine · Colorado Springs, CONPI 1578856217
Payments from drug & device makers
Across 83 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$192
- Pfizer$122
- Novo Nordisk$106
- Merck$97
- Lilly USA, LLC$96
- Inspire Medical Systems, Inc.$86
- plus $938 from 28 others
What the payments were for
- Food & beverage$1,636100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $192 |
| Pfizer | 6 | $122 |
| Novo Nordisk | 6 | $106 |
| Merck | 4 | $97 |
| Lilly USA, LLC | 7 | $96 |
| Inspire Medical Systems, Inc. | 1 | $86 |
| AbbVie | 3 | $72 |
| Alkermes, Inc. | 3 | $70 |
| Amgen(2 entities) | 4 | $67 |
| GSK | 3 | $66 |
| Novartis | 3 | $63 |
| Boston Scientific | 3 | $63 |
| Hologic Sales And Service, LLC | 3 | $61 |
| Exact Sciences | 3 | $51 |
| Astellas Pharma US Inc | 2 | $50 |
| Dexcom, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Viiv Healthcare Company | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Medtronic | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Phadia US Inc. | 1 | $11 |
How this compares
$1,636 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $70,668 |
| RybelsusSemaglutide | 18 | $41,503 |
| JardianceEmpagliflozin | 19 | $28,154 |
| EliquisApixaban | 19 | $23,375 |
| FarxigaDapagliflozin Propanediol | 20 | $16,832 |
| LinzessLinaclotide | 11 | $15,588 |
| InvokanaCanagliflozin | 13 | $15,022 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,389 |
| Levothyroxine Sodium | 175 | $1,809 |
| Levemir FlexpenInsulin Detemir | 15 | $1,461 |
| Rosuvastatin Calcium | 128 | $1,445 |
| SynthroidLevothyroxine Sodium | 13 | $1,206 |
| Omeprazole | 66 | $1,182 |
| Tramadol Hcl | 35 | $1,163 |
| Atorvastatin Calcium | 147 | $1,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $106 | $112,17060 claims |
| Boehringer IngelheimJardiance | $19 | $28,15419 claims |
| PfizerEliquis | $122 | $23,37519 claims |
| AstraZenecaFarxiga | $192 | $16,83220 claims |
| AbbVieLinzess, Synthroid | $72 | $16,79424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Colorado Springs
- Ripley HollisterColorado Springs$5.5M
- Matthew YoungColorado Springs$270K
- Lawrence AndrewsColorado Springs$102K
- Jeffrey SnyderColorado Springs$31K
- Elizabeth EricksonColorado Springs$31K
- Daniel RohwederColorado Springs$21K
- Stephen FarkasColorado Springs$20K
- Max NevarezColorado Springs$15K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.